Recent research on tofacitinib in the treatment of pediatric rheumatic diseases.
10.7499/j.issn.1008-8830.2201081
- Author:
Shi-Hai ZHOU
1
;
Ya-Qun XIONG
1
;
Ya CHEN
1
Author Information
1. Department of Pharmacy, Guihang Guiyang Hospital, Guiyang 550001, China.
- Publication Type:Review
- Keywords:
Child;
Janus kinase-signal transducer and activator of transcription signaling pathway;
Rheumatic disease;
Tofacitinib
- MeSH:
Adult;
Child;
Humans;
Janus Kinases/metabolism*;
Piperidines/therapeutic use*;
Protein Kinase Inhibitors/therapeutic use*;
Pyrimidines/therapeutic use*;
Rheumatic Diseases/drug therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(4):447-453
- CountryChina
- Language:Chinese
-
Abstract:
Tofacitinib is a Janus kinase inhibitor and can block the Janus kinase-signal transducer and activator of transcription signal transduction pathway and reduce the production and release of a variety of cytokines. It has great potential in the treatment of various rheumatic diseases with a rapid onset of action and can reduce corticosteroid dependence and related adverse events. The therapeutic effect of tofacitinib in adult patients has been confirmed, and it has been increasingly used in pediatric patients in recent years. This article reviews the clinical application of tofacitinib in the treatment of pediatric autoimmune diseases.
